Similar Search Results

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

Nguyen Cuc Thi Thu; Petrelli, Fabio; Scuri, Stefania; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 5, pp. 763-777

Persistent link: https://www.econbiz.de/10012061274

Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany

Schwander, Bjoern - In: Health economics review 4 (2014) 27, pp. 1-10

The next generation of artificial vision devices (AVDs), which is currently developed in pre-clinical settings, has the potential to improve the vision of blind patients with retinitis pigmentosa (RP) in a manner that they will be categorized as visual impaired but no more as blind. This...

Persistent link: https://www.econbiz.de/10010526936

Stratified medicine in schizophrenia : how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?

Jin, Huajie; McCrone, Paul; MacCabe, James H. - In: The European journal of health economics : HEPAC ; … 20 (2019) 9, pp. 1425-1435

Persistent link: https://www.econbiz.de/10012221385

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

Holleman, Marscha S.; Al, Maiwenn J.; Zaim, Remziye; … - In: The European journal of health economics : HEPAC ; … 21 (2020) 1, pp. 153-164

Persistent link: https://www.econbiz.de/10012221645

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in Ch...

Liu, Huiqin; Wang, Ying; He, Qi - In: Health economics review 12 (2022) 1, pp. 1-10

Objective In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC), the ORIENT …

Persistent link: https://www.econbiz.de/10013492965

Cost-effectiveness analysis of (accelerated) pre-operative versus (conventional) post-operative radiotherapy for patients with oral cavity cancer in Sweden

Silfverschiöld, Maria; Carlwig, Kristin; Jarl, Johan; … - In: The European journal of health economics 25 (2024) 1, pp. 177-185

Persistent link: https://www.econbiz.de/10014560516

Using "costs states" in a semi-Markov model to estimate cost-effectiveness with an illustration for metastatic HER2+ breast cancer in the Czech Republic

Slegerova, Lenka - 2020

2+ breast cancer. The aim is to assess the cost-effectiveness of adding pertuzumab to the combination of trastuzumab …

Persistent link: https://www.econbiz.de/10012242860

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

Paulissen, Jeroen H. J.; Seddik, Ahmed H.; Dunton, Kyle J. - In: The European journal of health economics 25 (2024) 4, pp. 689-699

Persistent link: https://www.econbiz.de/10014565096

Are biopharmaceutical budget caps good public policy?

Goldman, Dana P.; Lakdawalla, Darius; Baumgardner, James R. - In: The Economists' voice 13 (2016) 1, pp. 27-42

Persistent link: https://www.econbiz.de/10011585711

Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries

Hens, Manuel; Villaverde-Hueso, Ana; Alonso, Veronica; … - In: The European journal of health economics : HEPAC ; … 15 (2014) 4, pp. 433-437

Persistent link: https://www.econbiz.de/10010383394

1
2
3
4
5
6
7
8
9
10
Next
Last